FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY

BACKGROUND: (blind field). METHODS: Patients with recurrent high grade gliomas were enrolled in one of two arms. Group A patients (clinical assessment group) received a single intratumoral injection of DNX-2401 into biopsy-proven recurrent glioma. Group B patients (biological endpoint group) receive...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Lang, Frederick F., Conrad, Charles, Gomez-Manzano, Cande, Tufaro, Frank, Yung, WKA, Sawaya, Raymond, Weinberg, Jeffrey, Prabhu, Sujit, Fuller, Gregory, Aldape, Kenneth, Fueyo, Juan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2014
विषय:
abstracts
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144610/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou208.61
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन